Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PURPOSE: Although trastuzumab is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)- positive early breast cancer (EBC), drug resistance and disease relapse occur. Therefore, we performed a meta-analysis to assess the efficacy and safety of trastuzumab-containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Liuwen, Fu, Fangmeng, Li, Jing, Huang, Meng, Zeng, Bangwei, Lin, Yuxiang, Mei, Qian, Lv, Jinxing, Wang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102417/
https://www.ncbi.nlm.nih.gov/pubmed/32256583
http://dx.doi.org/10.1155/2020/5169278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102417/
https://www.ncbi.nlm.nih.gov/pubmed/32256583
http://dx.doi.org/10.1155/2020/5169278

Ejemplares similares